medigraphic.com
ISSN 0188-2198 (Impreso)

2003, Número 2

Siguiente >>

Rev Mex Cardiol 2003; 14 (2)


Estado posprandial y el riesgo de enfermedad cardiovascular, declaratoria de posición

Idioma: Español
Referencias bibliográficas: 57
Paginas: 39-50
Archivo PDF: 116.29 Kb.


FRAGMENTO

Las enfermedades cardiovasculares por aterosclerosis ocupan los primeros lugares de morbilidad y mortalidad en la población mexicana. El riesgo se incrementa en personas con diabetes mellitus o intolerancia a la glucosa, en donde representa la principal causa de muerte. Los resultados de estudios clínicos recientes han demostrado que es posible modificar la historia natural de las complicaciones microvasculares, incluyendo retinopatía, nefropatía y neuropatía diabética a través del control metabólico de la glucemia. Por lo que respecta a las complicaciones macrovasculares, se han identificado varios factores modificables:


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hayden MR, Tyagi SC. Is Type 2 diabetes mellitus a vascular disease (Atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovascular Diabetology 2003; 2: 2-11.

  2. National Cholesterol Education Program. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2487

  3. American Diabetes Association. Postprandial blood glucose. Consensus Statement. Diabetes Care 2001; 24: 775-778.

  4. Service F. Hall L. Effects of size, time of day and sequence of meal ingestion on Carbohydrate tolerance in normal subjects. Diabetologia 1983; 25:316-321.

  5. Dinneen S, Gerich J. Carbohydrate metabolism in non-Insuline dependent diabetes. N Engl J Med 1992; 327:707-713.

  6. Guerrero-Romero F, Rodríguez-Morán M. The Impaired Glucose Tolerance is a more advanced stage of alteration in the glucose metabolism than the Impaired Fasting Glucose. J Diabetes Complications 2001; 15(1): 34-37

  7. Polonsky K, Given B. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1998; 318:1231-1239.

  8. Howard B. Lipoprotein metabolism en Diabetes Mellitus. J Lipid Res 1987; 28: 613-628.

  9. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996; 347: 949-950.

  10. Lebovitz H. The postprandial state: managing its atherogenic potential. Am J Cardiol 2001; 88(6a): 1-3

  11. Ceriello A. The postprandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rew 2000; 16: 125-132.

  12. Lehto S, Ronnemaa T. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-age patients with DMNID. Diabetes 1997; 46: 1354-59.

  13. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the Pathogenesis of diabetic complications. Diabet Med 1998; 15: 188-193.

  14. Haffner S. The importance of hyperglycemia in the nonfasting state to the Development of cardiovascular disease. Endocr Rev 1998; 5: 583-592.

  15. Rewers M, Shetterly SM. Prevalence of coronary heart disease in subjects with normal And impaired glucose tolerance and non-insulin dependent diabetes mellitus in a Biethnic Colorado population. The San Luis Valley Diabetes Study. Am J Epidemiol 135: 132-1330.

  16. Zilversmit DB. Atherogenesis a postprandial phenomenon. Circulation 1979; 60: 473-485.

  17. Shichiri M, Kishkawa H, Ohkubo Y, Wake N. Long term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21-B29.

  18. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 997-986.

  19. Malmberg K for the DIGAMI Study Group. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512-1515.

  20. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII.

  21. Evaluation of insulin therapy. Final report. Diabetes 1982; 31 (Suppl 5): 1-26.-Abraira C, Colwell JA, Nuttall FQ et al, Cardiovascular events and correlates in the Veteran Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on glycemic control and complications in type 2 diabetes (VACSDM). Arch Intern Med 1997; 157:181-188.

  22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.

  23. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.

  24. The DECODE study Group: Glucose tolerance and mortality. Comparison of Who and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21.

  25. The DECODE Study Group on behalf of the Europen Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 2001; 161: 397-404.

  26. Rodríguez BL, Lau N, Burchfield CM et al. Glucose intolerance and 23-year risk of Coronary Heart Program. Diabetes Care 1999; 22: 1262-1265.

  27. Lowe LP, Liu K, Greenland P et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997; 20: 163-169.

  28. Barrett CE, Ferrera A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998; 21: 1236-1239.

  29. Shaw JE, Hodge AM, de Courten M et al. Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia 1999; 42: 1050-1054.

  30. Haller H. Postprandial glucose and vascular disease. Diabetic Med 1997; 14: S50-S56

  31. 28.-Kuusito J, Mykkaen L. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998: 15: 188.193.

  32. Pan XR, Hu YH. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care 1993; 16: 150-156.

  33. Baron A. Impaired Glucose Tolerance as a Disease. Am J Cardiol 2001; 88: (suppl) 16H-19H.

  34. Haffner SM. Impaired glucose tolerance: is it relevant for cardiovascular disease? Diabetología 1997; 40: (suppl.2) S138-140.

  35. Balkau B, Shipley M, Jarret RJ, Pÿoräla M, Forham A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-age non diabetic men. 20 year follow up in the Whitehall Study, the Paris Prospective Study and the Helsinky Policemen Study. Diabetes Care 1998; 21: 360-367.

  36. Gerstein CH, Yusufs. The Relationship Between Glucose and Inadent Cardiovascular Events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12 .4 years. Diabetes Care 1999; 22: 233-240.

  37. Guerrero-Romero F, Rodríguez-Morán M, González-Ortiz M, Martínez-Abundis E. Insulin action and secretion in healthy Hispanic-Mexican first-degree relatives of subjects with type 2 diabetes. J Endocrinol Invest 2001; 24: 580-586.

  38. Hanefeld M. Postprandial plasma glucose is a independent risk factor for increased carotid intima-medic thickness in non-diabetic individuals. Atherosclerosis 1999; 144:229-235.

  39. Temelkova-Kurktschievts. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fosting glucose or HbA1c level. Diabetes Care 2000; 23: 1830-1834.

  40. Benks PHJ. Carotid artery Stenosis is related to blood glucose level in an Elderly Caucasian population: The Hoorn Study. Diabetologia 1995; 38: 86-96.

  41. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association: The National Hert, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestiva and Kidney Diseases; and the American Heart Association. Circulation 1999; 100(10): 1132-380.

  42. Festa A, D’Agostino R Jr, Howard G et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin Resistance. Atherosclerosis Study. Circulation 2000; 102(1): 42-7

  43. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6 years Malmo feasibility study. Diabetologia 1991; 34: 891-898.

  44. Pan XR, Li GW, Hu YH. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.

  45. UK Prospective Diabetes Study (UKPDS). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.

  46. Tuomilehto J, Lindstrom J. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.

  47. Knowler WC. The Diabetes Prevention Program. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403

  48. Azew Sp, Peters RK, Berkowitz K, Kjos S, Xiang A, Buckacan TA. Tripod (triglitazone in the prevention of diabetes) randomized pincebo-control trial of traglitazone in women with prior gestacional diabetes. Control Clin Trials 1998; 19(2): 217-31

  49. Chiasson J. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-77.

  50. Chiasson JRG. Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: The Stop-NIDDM trial. Diabetologic 2002; 45 (suppl 2): A-104.

  51. Ratner RE. Controlling Postprandial Hyperglycemia. Am J Cardiol 2001; 88 (suppl): 26H-31H.

  52. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997; 26: 539-551.

  53. Fuhlendorff J, Rorsman P. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.

  54. Marbury T, Huang WFC. Repaglinide versus glyburide: a one year comparison. Diabetes Res Clin Pract 1999; 43: 155-166.

  55. Keilson L, Mather S. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 1081-1086.

  56. Mooradian AD, Thurman JE. Drug Therapy of postprandial hiperglycemia. Drugs 1999; 57:19-29. Christopher Grainger Parkin, MS.

  57. Is Postprandial Glucose Control important? Is it Practical in Primary Care Settings? Clinical Diabetes 2002; 20(2): 71-76.




2020     |     www.medigraphic.com